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Background: Chronic non-specific low back pain is the most common medical problem for which patients seek
complementary and alternative medical treatment, including bee venom acupuncture. However, the effectiveness
and safety of such treatments have not been fully established by randomized clinical trials. The aim of this study is
to determine whether bee venom acupuncture is effective for improving pain intensity, functional status and
quality of life of patients with chronic non-specific low back pain.
Methods/design: This study is a randomized, double-blinded, sham-controlled clinical trial with two parallel arms.
Fifty-four patients between 18 and 65 years of age with non-radicular chronic low back pain experiencing low back
pain lasting for at least the previous three months and ≥4 points on a 10-cm visual analog scale for
bothersomeness at the time of screening will be included in the study. Participants will be randomly allocated into
the real or sham bee venom acupuncture groups and treated by the same protocol to minimize non-specific and
placebo effects. Patients, assessors, acupuncturists and researchers who prepare the real or sham bee venom
acupuncture experiments will be blinded to group allocation. All procedures, including the bee venom
acupuncture increment protocol administered into predefined acupoints, are designed by a process of consensus
with experts and previous researchers according to the Standards for Reporting Interventions in Clinical Trials of
Acupuncture. Bothersomeness measured using a visual analogue scale will be the primary outcome. Back
pain-related dysfunction, pain, quality of life, depressive symptoms and adverse experiences will be measured using
the visual analogue scale for pain intensity, the Oswestry Disability Index, the EuroQol 5-Dimension, and the Beck’s
Depression Inventory. These measures will be recorded at baseline and 1, 2, 3, 4, 8 and 12 weeks.
Discussion: The results from this study will provide clinical evidence on the efficacy and safety of bee venom
acupuncture in patients with chronic non-specific low back pain.
Trial registration: This study is registered with the United States National Institutes of Health Clinical Trials Registry:
NCT01491321
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Chronic non-specific low back pain (CLBP) is a common
medical problem considered as a multifactorial disorder in
which musculoskeletal pain and psychosocial factors inter-
act with each other [1,2]. The socioeconomic impact of
CLBP is related to its greater comorbidities and more
frequent prescriptions of pharmacotherapies and other
adjunctive medications associated with these painful condi-
tions [3]. Despite of variable accessibility to conventional
treatments, patients with low back pain (LBP) have increas-
ingly been using complementary and alternative medicine
to alleviate their symptoms [4]. The tendency towards the
use of complementary and alternative medicine in CLBP
may reflect the deficits and unfulfilled patient expectations
in conventional medical treatment [5]. Therapeutic modal-
ities of complementary and alternative medicine, including
acupuncture, herbal medicine, thermal therapy and spinal
manipulative therapy, have been used in patients with
CLBP [5,6] but evidence of effectiveness has not been fully
established.
Bee venom acupuncture (BVA) involves injecting purified
and diluted bee venom into acupoints [7]. BVA exhibits
several pharmacological actions, including analgesic, anti-
inflammatory, anti-arthritic, and anti-cancer effects through
multiple mechanisms, such as activation of the central
inhibitory and excitatory systems and modulation of the
immune system [8]. The analgesic effects of BVA have been
reported in animal experiments [9,10] and in the clinic
[7,11]. Researchers have found that BVA could be a thera-
peutic option for alleviating LBP [7,12]. Recently, a cohort
study revealed that the bee venom integrative package,
which comprises herbal medicines, acupuncture and spinal
manipulation, is effective in the treatment of LBP with leg
pain [13]. However, there has been relatively little evidence
in clinical trials on BVA to treat CLBP, especially rigorous
randomized controlled clinical trials on the efficacy of BVA.
Therefore, a rigorous randomized controlled trial is needed
to develop clinical indications and a manual for the optimal
practical guidelines of BVA.
Aims
The purpose of this study is to determine whether BVA
is effective at improving pain intensity, functional status
and quality of life in patients with CLBP.
Methods/design
Design
This study is a randomized, double-blinded, sham-
controlled clinical trial with two parallel arms. We
intend to compare the effects of BVA and pharmaco-
therapy with sham-BVA and pharmacotherapy in
patients with CLBP. The trial is registered with the U.S.
National Institutes of Health Clinical Trials registry and
is approved by the Institutional Review Board of KyungHee University Hospital at Gangdong (KHUHGD). The
outcome assessment and the statistical analyses are per-
formed by professionals who are blinded to the assignment
of patients to the real or sham BVA group.Participants
Patients with non-radicular chronic LBP will be recruited
with a target sample size of 54 participants.
Inclusion criteria:
 Being between 18 and 65 years of age
 Experiencing LBP lasting for at least the previous
three months
 Scoring ≥4 points on a 10-cm visual analog scale
(VAS) for bothersomeness of LBP at the time of
screening
 Exhibiting no abnormalities on neurological
examination (for example, lumbosacral nerve
function, deep tendon reflexes, plantar response,
voluntary muscle activation and sensory function)
 Having non-specific, uncomplicated LBP, that is,
International Classification of Diseases-10 codes:
 M513 Other specified intervertebral disc
degeneration
 M545 Low back pain
 M548 Other dorsalgia
 M549 Dorsalgia, unspecified
 S335 Sprain and strain of lumbar spine
 S337 Sprain and strain of other and unspecified
parts of the lumbar spine and pelvis
 S336 Sprain and strain of sacroiliac joint




 Serious spinal disorders, including malignancy,
vertebral fracture, spinal infection and inflammatory
spondylitis
 Other chronic diseases that could affect or interfere
with the therapeutic outcomes, including
cardiovascular disease, diabetic neuropathy, active
hepatitis, fibromyalgia, rheumatoid arthritis,
dementia and epilepsy
 Previous spinal surgery or scheduled procedures
during the study
 Painful conditions induced by traffic accidents
 Chief musculoskeletal pain other than back pain
 Conditions where BVA might not be safe, including
clotting disorders, administration of an
anticoagulant agent, pregnancy and seizure disorders
 Documented hypersensitive reactions to previous
BVA treatments, bee stings or insect bites
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 Current use of corticosteroids, narcotics, muscle
relaxants or herbal medicines to treat LBP or any
medication considered inappropriate by the
investigator
 Pending lawsuit or receipt of compensation because
of LBP
 Refusal to participate in the trial or provide
informed consent
 Inability to read and write in the Korean languageRecruitment
Participants will be recruited through advertisements
in local newspapers, on hospital websites and on bul-
letin boards. If patients are interested in participation,
they will be asked to answer screening questions to
determine their eligibility. If eligible, they will be
guided through the informed consent process. After
written consent is obtained, a study researcher will
administer the baseline questionnaire then randomly
allocate the participants into the real or sham BVA
group. After randomization, the interviewer will
schedule the treatment procedure. All recruit proce-
dures will be recorded in a log file (Figure 1).Identify patients with chron
 and confirm willingness to 
trial
Obtain 54 par
Administer BVA with 
Western medicine treatment 
twice per week for three 
weeks
(n=27)
Assess outcomes at 0,
wee
Figure 1 Study sequence. Process of recruitment, randomization to treatmRandomization and blinding procedure
Randomization will be undertaken through a compu-
terized software randomization program by an inde-
pendent statistician who is concealed with respect to
the patients. Randomization will be performed only
after a participant is confirmed to be eligible and
written informed consent has been obtained. Partici-
pant details will be recorded, and the treatment arm
and randomization number will be allocated to the
patients; both of these are included in the partici-
pants’ hospital files. The randomization form will be
completed and returned to the principal investigator.
As a double-blinded randomized controlled trial,
the researcher performing the outcome measure
assessments will be blinded to the patient’s treatment
allocation. Furthermore, the people who administer
treatments will be blinded as to whether the patient
receives real or sham BVA, and the pharmacopunc-
tures will be prepared by independent researchers.
Education of acupuncturists
Licensed Korean medical doctors (KMDs) who are
specialized in acupuncture and moxibustion or orien-
tal rehabilitation medicine will take an educational
course to ensure their strict adherence to the study
protocol and familiarity with administering studyic low back pain
participate in the 
ticipants 
Carry out randomization
Administer sham BVA with 
Western medicine treatment 




over three weeks 
 1, 2, 3, 4, 8, and 12
ks
ent and outcome assessment.




(a) Style of acupuncture Traditional Korean medicine theory
(b) Reasoning for treatment provided (based on
historical context, literature sources and consensus
methods)
Textbook on acupuncture and moxibustion-related articles (published
trials) [14]
(c) Extent to which treatment was varied Within 10 predefined acupoints
2. Details of
needling
(a) Number of needle insertions per patient per session Within 10 acupoints
(b) Names (or location if no standard name) of points
used (uni/bilateral)
Shenshu (BL23), Qihaishu (BL24), Dachangshu (BL25), Huantiao (GB30),
Yaoyangguan (GV3), Mingmen (GV4), Xuanshu (GV5)
(c) Depth of insertion 5 to 10 mm (subcutaneous)
(d) Response sought (for example, de qi or muscle twitch
response)
Penetrating, sharp, aching and painful sensations when penetrating
the skin. Spreading and lumpish sensation around the injection site.
Skin stimulation by bee venom in BVA group.
(e) Needle stimulation (for example, manual, electrical) Pharmacopuncture
(f) Needle-retention time None
(g) Needle type (diameter, length and manufacturer or
material)
1.0 ml disposable syringe (26-gauge needle) produced by Green Cross
Medical Equipment (Seoul, Korea)
3. Treatment
regimen
(a) Number of treatment sessions Six




(a) Details of other interventions administered to the
acupuncture group
Brochure with information about chronic low back pain, lifestyle
advice
(b) Setting and context of treatment, including
instructions to practitioners and information and
explanations to patients
Independent researcher counseling regarding treatment, lifestyle
management of low back pain
5. Practitioner
background
(a) Description of participating acupuncturists Korean medical doctors who are specialists of acupuncture and
moxibustion or oriental rehabilitation medicine, with more than three




(a) Rationale for the control or comparator in the





(b) Precise description of the control or comparator if
sham acupuncture
Double blind: In the sham BVA group, normal saline was used
instead of BVA. Both real and sham BVA were subcutaneously injected
into predefined acupoints through identical manipulation techniques
and the assessor, acupuncturist and patients were uninformed about
allocation.
Explanations given to patients: Explanation of real or sham BVA was
given to patients before randomization.
Details of sham BVA: Acupuncture points used, needle type, depths
of insertion, responses, needle stimulation and needle retention time
were identical in each group. The only difference was that normal
saline was used for injection.
Injection and increment protocol: The BVA group was prepared by
a predefined weekly increment protocol as follows: 0.2 ml for the first
week, 0.4 ml for the secondweek and 0.8 ml for the third week. The
sham BVA group was injected with normal saline at the same volume
as the BVA group. The predefined points were carefully selected by a
process of consensus with the participating Korean medical doctor.
BVA: bee venom acupuncture.
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intensive and customized training for a full under-
standing of the BVA increment protocol, including
details such as acupuncture points and weekly dose
increments of pharmacopuncture.Description of all interventions and comparisons
Treatment details
Both the real and sham BVA groups will receive a total
of six pharmacopuncture sessions over three weeks. In
the BVA group, 26-gauge sterile disposable syringes
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with normal saline (0.9% NaCl) will be used, whereas
normal saline without bee venom with the same dose
will be used in the sham BVA group. A skin hypersensi-
tivity test will be performed on all the patients at LI 11
acupoints with subcutaneous injections of 0.05 ml of
1:20,000 bee venom preparation. Local swelling over
10 mm in diameter or redness over 20 mm in diameter
will be considered positive reactions, and these patients
will be excluded from this study. At the first pharmaco-
puncture session, all participants will receive a copy of
the Exercise Manual for Patients with Low Back Pain
from the spine center of KHUHGD and will be encour-
aged to exercise according to the manual during the en-
tire treatment period. As a rescue therapy to minimize
the risk of disease deterioration during the trial period,
all the participants will be prescribed loxonin (Loxopro-
fen, 60 mg/tablet; Dong Wha Pharm Co., Ltd., Seoul,
Korea) per os one tablet three times a day throughout
the treatment period.
Bee venom treatment protocol
BVA will be prepared as dried bee venom powder (Yoomil
Garden, Hwasun, Korea) then diluted and filtered in
normal saline (1:20,000) at the Traditional Korean Medical
Pharmacy at KHUHGD. After sterile skin preparation,
patients from both real and sham BVA group will be sub-
cutaneously injected perpendicularly at a depth of 0.5 cm
to 1.0 cm with the patient lying in a prone position. Phar-
macopuncture will be prepared by a predefined weekly in-
cremental protocol as follows; 0.2 ml for the first week,
0.4 ml for the secondweek and 0.8 ml for the third week.
Patients in the sham BVA group will be injected with the
same volume as those in the BVA group. The predefined
points are carefully selected by a process of consensus
among participating KMDs who are all experienced in the
treatment of LBP. Acupuncturists can select up to 10
points from predefined acupoints as a reflection of daily
practice, in which the acupuncture points are varied based
upon changes of patient symptoms or pain (Table 1).
Data collection
A series of measurements to assess back pain-related
dysfunction, pain, quality of life and adverse experiences
will be collected at baseline and week 1, 2, 3, 4, 8 and 12.
At the screening visit, patients will be asked to fill out a
questionnaire regarding their sociodemographic characte-
ristics, including age, gender, marital status, residence,
occupation and education level. A medical history will be
also taken before their physical check-ups, and these factors
will determine their eligibility for our study. Participation in
can be ended at any stage if the patient refuses to continue
or in the presence of significant clinical deterioration, as
determined by the attending KMD researchers. For thoseparticipants who will be lost to follow-up and who drop
out, intention-to-treat analysis will be applied to the exist-
ing data (Table 2).
Primary outcome measurements
Bothersomeness from LBP will be assessed using the 10-cm
VAS for bothersomeness of LBP [18]. To evaluate the clin-
ical severity and impact on activities of daily life in patients
with CLBP, the VAS for bothersomeness is selected as a pri-
mary outcome measurement. Using the 10-cm VAS (0, ab-
sence of bothersomeness; 10, the worst bothersomeness
imaginable), the patient will be asked to report the degree
of bothersomeness from LBP within the past week. Bother-
someness of LBP will be measured at every single visit at
baseline and 1-, 2-, 3-, 4-, 8- and 12-week follow-ups after
beginning treatment. The primary end point is the third
week follow-up, which marks the end of the six pharmaco-
puncture sessions.
Secondary outcome measurements
VAS for pain intensity: The pain intensity of LBP will be
assessed using the 10-cm VAS for LBP [19,20]. This inven-
tory is a fast and straightforward method for evaluating the
subjective degree of pain. Pain intensity will be measured in
the same fashion as VAS for bothersomeness (0, absence of
pain; 10, the worst pain imaginable) at every single visit at
baseline and 1-, 2-, 3-, 4-, 8- and 12-week follow-up visits
after beginning treatment.
The Oswestry Disability Index (ODI): Back pain related
dysfunction will be assessed using the ODI [21]. The ODI
contains 10 questions about daily activities, including
inventories of pain intensity, personal care, lifting, walking,
sitting, standing, sleeping, sexual life, social life and travel-
ing. Each question is rated on a scale from 0 to 5 points;
the lower the score, the less disabled the person is by the
pain. The validated Korean Version of the ODI [22] will be
administered at baseline and 1-, 2-, 3-, 4-, 8- and 12-week
follow-up visits after beginning treatment.
The EuroQol 5-Dimension (EQ-5D): Quality of life for
patients with LBP will be assessed using the Korean version
of the EQ-5D [23,24]. The EQ-5D includes generic ques-
tions about quality of life as it relates to personal health.
This inventory has two parts. In the first part, tthe patient
evaluates his or her health state with respect to five dimen-
sions in a descriptive way: mobility, personal care, daily
activities, pain or discomfort, and anxiety or depression.
Each dimension is scored on a scale from 1 to 3; the lower
the score, the better the state of health of the test taker. In
the second part, the patient rates his or her overall state of
health on the day the questionnaire is completed using a
VAS scale from 0, which is the worst imaginable state of
health, to 100, the best possible state of health. The two
scores are complementary. The EQ-5D has an index of
reference value of possible health profiles ranging from a
Table 2 Schedule for data collection: outcome measures per visit
Measures Baseline (Week 0) Week 1 Week 2 Week 3 Week 4 Week 8 Week 12
Sociodemographic characteristics x
Back pain history x
X-ray x
Visual analogue scale for bothersomeness of low back pain x x x x x x x
Visual analogue scale for pain intensity of low back pain x x x x x x x
Oswestry Disability Index x x x x x x x
EuroQol-5D x x x x x x x
Beck's Depression Inventory x x x x x x x
Adverse experiencesa x x x x x
Credibility testb x x
a. Adverse experiences : Any adverse experiences at any visit during treatment sessions and 12 weeks will be monitored. The research team will review all trial
protocols, monitor patient safety and investigate any adverse events. b. Credibility test : The credibility of the real and sham treatments will be assessed using the
validated Korean version of the credibility test.
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5D will be administered at baseline and 1-, 2-, 3-, 4-, 8- and
12-week follow-up visits after treatment begins.
Beck’s Depression Inventory (BDI): Depressive symptoms
from LBP will be assessed by the Korean version of BDI
[25,26]. The BDI includes 21 items and is a self-
administered questionnaire. Each item has a response
format ranging from 0 to 3, giving a theoretical maximum
score of 63. The BDI will be administered at baseline and
1-, 2-, 3-, 4-, 8- and 12-week follow-ups after beginning
treatment.
Credibility test: The credibility of the real and sham treat-
ments will be assessed using the validated Korean version
of the credibility test at baseline and again at the end of
treatment [27]. The participants will rate the credibility of
the treatment by answering four questions on a numeric
rating scale, with 0 being not at all and 6 for maximal
agreement:
1. improvement expected;
2. recommendation to others;
3. treatment logical;
4. effective also for other diseases.
Safety
Any adverse experiences at any visit during the six treat-
ment sessions will be monitored. The research team will
review all trial protocols, monitor patient safety and investi-
gate any adverse events, which are defined as treatment-
related experiences.
Withdrawal and dropout
Participation will be ended at any stage if the patient refuses
to continue, withdraws consent, violates inclusion or exclu-
sion criteria or the trial protocol, or completes less thanfour treatment sessions as determined by the attending
KMD researchers. The trial will be stopped if the principle
investigator believes that there are unacceptable risks of
serious adverse events.
Sample size determination
We have performed sample size calculations for CLBP
according to another acupuncture study on the same
disease using the same primary outcome measure
because no such BVA research has been reported [28].
The expected mean difference and common standard
deviation between the two groups are estimated (mean
difference = 1.5, SD = 2.73) according to that former
acupuncture research [28] on CLBP using the 10-cm
VAS as a primary outcome measure. For two arms
(control-sham BVA and experimental-BVA), we consider
the two-sample t-test model. Twenty-seven participants
will be required per intervention group to achieve 0.80
power (1-β) at the 0.05 α level after adjusting for a 20%
attrition rate.
Data analysis
The statistical analysis will be performed in the principle
of intention-to-treat analysis and per-protocol analysis.
For the intention-to-treat analysis, data will be processed
with the last observation carried forward method.
A homogeneity test of the baseline characteristics will be
performed on both demographical and clinical data using a
two-sample t-test for quantitative data and a chi-square test
for qualitative data. The two-sample t-test will be used for
the VAS to evaluate the bothersomeness of LBP at baseline
and again at four weeks (primary endpoint) for the com-
parison of the two groups and to determine differences
from baseline. For each outcome variable, an analysis of
covariance will be performed on the data to adjust the
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treatment interactions will be explored using a repeated-
measures analysis of variance. A chi-square test or a Fisher’s
exact test will be performed to determine the difference
between groups and the adverse effects, which will be
recorded and described as frequency and percentage. All
statistical analyses will be carried out with the Statistical
Package for the Social Sciences (SPSS, Inc., Chicago, IL,
USA) for Windows version 18.0, and a significance level of
0.05 will be used.
Data handling
Investigators will enter the information required by the
protocol into the case report forms. Non-obvious errors or
omissions will be put into data query forms, which will be
used for the researchers’ workshop. The data will be ga-
thered and summarized with respect to demographic base-
line characteristics, effectiveness and safety observations.
Discussion
The results from this study will determine the efficacy and
safety of BVA on CLBP as an adjunctive treatment to
pharmacotherapy that reflects daily practice. These results
can provide clinical evidence regarding whether BVA can
be beneficial in pain alleviation and changing disease-
related functional status.
Previous randomized clinical trials that compared the
efficacy of BVA with acupuncture or normal saline injection
on LBP [29,30] have been underestimated due to their poor
methodological quality. In this study, participants from
both the real and sham BVA groups will be treated by the
same protocol to minimize the non-specific and placebo
effects. All procedures (including the BVA increment
protocol administered into predefined acupoints) have been
rigorously designed by a process of consensus with experts
and previous research according to the Standards for
Reporting Interventions in Clinical Trials of Acupuncture.
However, the blinding and allocation concealment could be
compromised by the manifestation of a bee-venom-specific
response in patients in our experimental group, including
pain, swelling, redness of the skin and itching, which could
be perceived by patients. We will try to blind and conceal
group allocation between patients, assessors, acupuncturists
and researchers by having an independent researcher
prepare both real and sham BVA procedures. The results of
this trial will be available in August 2013.
Trial status
The trial is currently in the recruitment phase.
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